FDA took to the pages of the New England Journal of Medicine Oct. 8 to emphasize to physicians that the recently approved obesity drugs Belviq (lorcaserin) from Arena Pharmaceuticals Inc. and Qsymia (topiramate/phentermine) from Vivus Inc. are not for people seeking “to lose a few pounds for cosmetic purposes.”
“It is important that their use be limited to patients for whom they are indicated,” FDA officials insisted
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?